A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

2004569 citationsJournal Articlebronze Open Access

Authors

Adnan Kastrati · Deutsches Herzzentrum der Charité

Julinda Mehilli · Deutsches Herzzentrum der Charité

Helmut Schühlen · Deutsches Herzzentrum der Charité

Josef Dirschinger · Klinikum rechts der Isar

Franz Dotzer · Garmisch-Partenkirchen Medical Center

Jurriën M. ten Berg · St. Antonius Ziekenhuis

Franz‐Josef Neumann

Abstract

Our data suggest that in patients at low-to-intermediate risk who undergo elective percutaneous coronary intervention after pretreatment with a high loading dose of clopidogrel, abciximab is associated with no clinically measurable benefit within the first 30 days.

Topics & Keywords

Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Coronary Interventions and Diagnostics

Publication Details

Published in: New England Journal of Medicine

Volume 350, Issue 3, pp. 232-238

DOI: 10.1056/nejmoa031859

Field-Weighted Citation Impact: 45.79

Command Palette

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

Authors

Abstract

Topics & Keywords

Publication Details